Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCDO in chronic wound healing
NCT07096830Not yet recruiting
- Start
- Aug 2025
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of tetrachlorodecaoxide in Chronic wound (2 arms). Primary endpoint: Percentage reduction in wound area at 4 weeks. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
tetrachlorodecaoxide
03
Conditions
Chronic wound
Beyond the preview
Go deeper on NCT07096830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07096830.